Last edition
News about Drug Discovery & Development
Shield Therapeutics secures expanded U.S. Food and Drug Administration approval for ACCRUFeR (ferric maltol) to treat iron deficiency in pediatric patients aged 10 and above, addressing a major unmet need.
Drug Discovery & Development | 20/02/2026 | By News Bureau | 127
GRAIL Reports Topline Results from NHS-Galleri Trial of Multi-Cancer Early Detection Test
Results from the NHS-Galleri trial show that annual multi-cancer screening with the Galleri test reduced Stage IV diagnoses and significantly increased early cancer detection across England’s NHS population.
Drug Discovery & Development | 20/02/2026 | By News Bureau | 289
Merck and Mayo Clinic Partner to Accelerate AI-Driven Drug Discovery and Development
Merck, known as MSD outside the United States and Canada, has entered into a strategic research and development agreement with Mayo Clinic, one of the world’s leading hospital systems, to advance the use of artificial intelligence (AI), advanced analytics and multimodal clinical data in drug discovery and development.
Drug Discovery & Development | 20/02/2026 | By Darshana | 109
GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults
New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.
Drug Discovery & Development | 19/02/2026 | By News Bureau | 135
The global molecular diagnostics market is projected to reach USD 38.01 billion by 2034, according to a new report by Polaris Market Research. The study provides an in-depth assessment of market size, share, emerging trends, and growth forecasts from 2025 to 2034, highlighting the sector’s expanding role in modern healthcare.
Drug Discovery & Development | 19/02/2026 | By Darshana | 105
Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review
Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.
Drug Discovery & Development | 18/02/2026 | By News Bureau | 156
GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP
European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.
Drug Discovery & Development | 18/02/2026 | By News Bureau | 119
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Drug Discovery & Development | 16/02/2026 | By News Bureau | 130
US Food and Drug Administration has accepted the supplemental New Drug Application submitted by Biofrontera for its photodynamic therapy product Ameluz, used with the RhodoLED red-light lamp system, for the treatment of superficial basal cell carcinoma.
Drug Discovery & Development | 15/02/2026 | By Darshana | 109
Syngene Partners with Johns Hopkins University for Early Drug Discovery
The collaboration between Syngene International and John Hopkins University is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research.
Drug Discovery & Development | 13/02/2026 | By News Bureau | 120
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy